PL2698166T3 - Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów - Google Patents
Hamowanie układu dopełniacza służące do lepszej regeneracji nerwówInfo
- Publication number
- PL2698166T3 PL2698166T3 PL13181901T PL13181901T PL2698166T3 PL 2698166 T3 PL2698166 T3 PL 2698166T3 PL 13181901 T PL13181901 T PL 13181901T PL 13181901 T PL13181901 T PL 13181901T PL 2698166 T3 PL2698166 T3 PL 2698166T3
- Authority
- PL
- Poland
- Prior art keywords
- nerve regeneration
- complement inhibition
- improved nerve
- improved
- complement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85027706P | 2006-10-10 | 2006-10-10 | |
EP07834628A EP2073898A1 (en) | 2006-10-10 | 2007-10-10 | Complement inhibition for improved nerve regeneration |
EP13181901.3A EP2698166B1 (en) | 2006-10-10 | 2007-10-10 | Complement inhibition for improved nerve regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2698166T3 true PL2698166T3 (pl) | 2016-03-31 |
Family
ID=38857887
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15187453T PL3028716T3 (pl) | 2006-10-10 | 2007-10-10 | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
PL13181901T PL2698166T3 (pl) | 2006-10-10 | 2007-10-10 | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15187453T PL3028716T3 (pl) | 2006-10-10 | 2007-10-10 | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
Country Status (16)
Country | Link |
---|---|
US (4) | US8703136B2 (pl) |
EP (4) | EP2698166B1 (pl) |
JP (2) | JP2010505946A (pl) |
AU (1) | AU2007307375B2 (pl) |
CA (3) | CA2980614A1 (pl) |
CY (1) | CY1123734T1 (pl) |
DK (2) | DK3028716T3 (pl) |
ES (2) | ES2831325T3 (pl) |
HK (2) | HK1194688A1 (pl) |
HU (2) | HUE026042T2 (pl) |
LT (1) | LT3028716T (pl) |
NZ (1) | NZ576195A (pl) |
PL (2) | PL3028716T3 (pl) |
PT (2) | PT3028716T (pl) |
SI (2) | SI2698166T1 (pl) |
WO (1) | WO2008044928A1 (pl) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE026042T2 (en) | 2006-10-10 | 2016-05-30 | Regenesance B V | Complement inhibition for improved nerve regeneration |
AU2014200822B2 (en) * | 2006-10-10 | 2016-01-28 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
WO2010005310A2 (en) * | 2008-07-10 | 2010-01-14 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Complement antagonists and uses thereof |
AU2009283889A1 (en) * | 2008-08-20 | 2010-02-25 | The Trustees Of Columbia University In The City Of New York | Complement inhibitors for treatment of injury from intracerebral hemorrhage |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
CN103687878B (zh) | 2011-07-22 | 2018-01-09 | 德国杰特贝林生物制品有限公司 | 抑制性的抗因子xii/xiia单克隆抗体及其用途 |
EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
AU2013334229B2 (en) | 2012-10-25 | 2018-02-15 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
CN104884088B (zh) | 2012-11-02 | 2018-06-15 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
CA2901225C (en) | 2013-03-08 | 2023-09-19 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
BR112016029076B1 (pt) | 2014-06-12 | 2024-02-15 | Ra Pharmaceuticals, Inc | Polipeptídeo e composição compreendendo o mesmo para inibir a clivagem de c5 em um sistema celular |
JP6738348B2 (ja) * | 2014-12-19 | 2020-08-12 | リジェネサンス ベスローテン フェンノートシャップ | ヒトc6に結合する抗体およびその使用 |
PL3250230T3 (pl) | 2015-01-28 | 2022-02-14 | Ra Pharmaceuticals, Inc. | Modulatory aktywności dopełniacza |
JP7005483B2 (ja) | 2015-04-06 | 2022-02-10 | バイオベラティブ ユーエスエー インコーポレイテッド | ヒト化抗C1s抗体及びその使用方法 |
CA3007772A1 (en) | 2015-12-16 | 2017-06-22 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
CA3011819A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Compositions and methods for inhibiting factor d |
KR102534895B1 (ko) | 2016-06-14 | 2023-05-24 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 및 이의 용도 |
MX2019006527A (es) | 2016-12-07 | 2019-08-01 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
US20210000927A1 (en) | 2017-12-04 | 2021-01-07 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
CN111630065A (zh) | 2017-12-13 | 2020-09-04 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
JP7110491B2 (ja) | 2018-12-13 | 2022-08-01 | アルジェニクス ビーブイ | ヒト補体因子c2bに対する抗体及び使用方法 |
CA3131927A1 (en) | 2019-03-08 | 2020-09-17 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
JP2022527508A (ja) | 2019-03-29 | 2022-06-02 | ラ ファーマシューティカルズ インコーポレイテッド | 補体モジュレータ及び関連方法 |
AU2020261059A1 (en) | 2019-04-24 | 2021-10-14 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
WO2021231210A1 (en) | 2020-05-11 | 2021-11-18 | Genentech, Inc. | Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same |
JP2023527684A (ja) | 2020-05-11 | 2023-06-30 | ジェネンテック, インコーポレイテッド | 神経疾患を治療するための補体成分c1s阻害剤、並びにそれを使用する関連組成物、システム及び方法 |
CN115698290A (zh) | 2020-05-11 | 2023-02-03 | 基因泰克公司 | 用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法 |
WO2024081954A2 (en) | 2022-10-14 | 2024-04-18 | Sanegene Bio Usa Inc. | Small interfering rna targeting c3 and uses thereof |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
IL89790A (en) | 1988-04-01 | 2002-05-23 | Johns Hopking University | Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5177190A (en) | 1989-01-03 | 1993-01-05 | Merck & Co., Inc. | Purified C5a receptor from human polymorphonuclear leukocytes |
JPH05503001A (ja) | 1989-10-27 | 1993-05-27 | スティッチング セントラール ラボラトリウム ファン デ ブルートトランスフュジエディエンスト ファン ヘット ネデールランツェ ローデ クルイス | C1インヒビターミューティンおよびその利用 |
GB9007971D0 (en) | 1990-04-09 | 1990-06-06 | Imutran Ltd | Pharmaceutical formulations |
WO1992022320A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
DE4222534A1 (de) * | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
DE4227762A1 (de) | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
US5480974A (en) | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
JP4077030B2 (ja) | 1993-09-01 | 2008-04-16 | ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス | 急性心筋梗塞中の心筋傷害の低減方法 |
US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
JPH09510088A (ja) | 1994-03-03 | 1997-10-14 | アレクション・ファーマシューティカル・インク | 最終補体インヒビター融合遺伝子およびタンパク質 |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5679345A (en) * | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
SE9503495L (sv) | 1995-10-09 | 1997-04-10 | Actinova Ltd | Nytt protein |
US5843884A (en) | 1995-11-15 | 1998-12-01 | Oklahoma Medical Research Foundation | C9 complement inhibitor |
US5922690A (en) | 1996-04-25 | 1999-07-13 | Van Gorp; Cornelius L. | Dermatan disulfate, an inhibitor of thrombin generation and activation |
ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
AU756490B2 (en) | 1997-08-26 | 2003-01-16 | Abgenix, Inc. | A process for inhibiting complement activation via the alternative pathway |
ATE249241T1 (de) | 1997-10-28 | 2003-09-15 | Univ British Columbia | Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem- myelins der saügetiere und förderung der nerven- regenerierung |
WO1999037681A2 (en) | 1998-01-26 | 1999-07-29 | Unilever Plc | Method for producing antibody fragments |
US6503947B1 (en) | 1998-01-27 | 2003-01-07 | Brigham And Women's Hospital | Method of treating cytotoxic damage |
AU3066699A (en) | 1998-03-03 | 1999-09-20 | Johns Hopkins University, The | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
US20030096775A1 (en) | 2001-10-23 | 2003-05-22 | Isis Pharmaceuticals Inc. | Antisense modulation of complement component C3 expression |
WO2000029033A2 (en) * | 1998-11-17 | 2000-05-25 | The General Hospital Corporation | A method of genetic vector delivery |
CA2347734A1 (en) | 1998-12-15 | 2000-06-22 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
BR9916765A (pt) | 1999-01-05 | 2001-09-25 | Unilever Nv | Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico |
EP1144616B2 (en) | 1999-01-19 | 2009-01-14 | Unilever Plc | Method for producing antibody fragments |
JP2003529536A (ja) | 1999-02-09 | 2003-10-07 | 3−ディメンショナル ファーマシューティカルズ, インコーポレイテッド | C1s介在疾患および状態の処置法、およびそれのための化合物および組成物 |
EP1169453A1 (en) | 1999-04-22 | 2002-01-09 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
EP1173200A1 (en) | 1999-04-28 | 2002-01-23 | University Of British Columbia | Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
DK1233987T3 (da) | 1999-11-29 | 2009-09-28 | Bac Ip B V | Immobiliserede enkelt-domæne antigenbindende molekyler |
AU1859201A (en) | 1999-11-29 | 2001-06-12 | Unilever Plc | Immobilisation of proteins |
DE60132169T2 (de) | 2000-01-31 | 2008-12-11 | Pharming Intellectual Property Bv | Humaner c1 inhibitor hergestellt in der milch transgener säugetiere |
ES2324280T3 (es) | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
WO2002048193A2 (en) | 2000-12-13 | 2002-06-20 | Unilever N.V. | Camelidae antibody arrays |
DE10112617A1 (de) * | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
US20030049260A1 (en) * | 2001-07-26 | 2003-03-13 | Leonard Bell | Method of improving cognitive function |
EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
CA2471116A1 (en) | 2001-12-21 | 2003-07-03 | Serge Muyldermans | Method for cloning of variable domain sequences |
CA2471645A1 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
AU2003286004A1 (en) | 2002-11-08 | 2004-06-07 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
MXPA05004955A (es) | 2002-11-08 | 2005-11-17 | Ablynx Nv | Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos. |
EP1569685B8 (en) | 2002-11-15 | 2012-12-05 | MUSC Foundation For Research Development | Complement receptor 2 targeted complement modulators |
JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン.ヴェー. | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
CA2515453C (en) | 2003-02-21 | 2013-09-24 | Tanox, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
US7544853B2 (en) * | 2003-05-16 | 2009-06-09 | Pharming Intellectual Property B.V. | C1 inhibitor with short half-life transient treatment |
US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
WO2005016285A2 (en) | 2003-08-13 | 2005-02-24 | New York University | Compositions and methods for inhibiting slit protein and glypican interactions |
US20060233776A1 (en) * | 2003-08-19 | 2006-10-19 | Norbert Heimburger | C1-inh as a drug for treating viruses pathogenic to humans |
WO2005025509A2 (en) | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
EP2340850A1 (en) | 2004-02-10 | 2011-07-06 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor B, the alternative complement pathway and methods related thereto |
KR20070036033A (ko) | 2004-03-26 | 2007-04-02 | 프로믹스 피티와이 리미티드 | 보체 C5a 수용체 조절제를 이용한 신경계 증상의치료방법 |
PL1755674T3 (pl) | 2004-05-14 | 2015-05-29 | Alexion Pharma Inc | Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza |
EP1674580A1 (en) | 2004-12-23 | 2006-06-28 | F. Hoffmann-La Roche Ag | Method for identifying activators and/or inhibitors of enzyme activity |
EP1863514A2 (en) | 2005-04-01 | 2007-12-12 | UMC Utrecht Holding B.V. | Therapeutic use of scin, a staphylococcal complement inhibitor in inflammatory diseases |
EP1885398B1 (en) * | 2005-05-26 | 2015-07-08 | The Regents of the University of Colorado, a body corporate | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
WO2006131874A2 (en) | 2005-06-06 | 2006-12-14 | Univ Cape Town | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
EP1738763A1 (en) * | 2005-06-30 | 2007-01-03 | AVANT Immunotherapeutics, Inc. | Use of complement inhibitory proteins to treat spinal cord injury |
US20070004625A1 (en) * | 2005-06-30 | 2007-01-04 | Li Liang-Man | Use of complement inhibitory proteins to treat spinal cord injury |
JP2007008876A (ja) | 2005-06-30 | 2007-01-18 | Avant Immunotherapeutics Inc | 脊髄損傷を治療するための補体阻害タンパク質の使用 |
CN101073584B (zh) | 2005-10-14 | 2012-10-10 | 全面技术公司 | 改变细胞功能的方法和组合物 |
US20070093443A1 (en) | 2005-10-21 | 2007-04-26 | Madison Edwin L | Modified proteases that inhibit complement activation |
MY151064A (en) | 2005-11-04 | 2014-03-31 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
KR101508668B1 (ko) * | 2005-12-21 | 2015-04-06 | 파밍 인텔렉츄얼 프라퍼티 비.브이. | 허혈-재관류 손상의 예방을 위한 c1 억제제의 용도 |
ES2530637T3 (es) | 2006-03-02 | 2015-03-04 | Alexion Pharma Inc | Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento |
JP5238695B2 (ja) | 2006-06-15 | 2013-07-17 | イースタン バージニア メディカル スクール | アストロウイルスコートタンパク質およびその誘導体を使用して補体カスケードタンパク質を調節するための方法 |
GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
HUE026042T2 (en) | 2006-10-10 | 2016-05-30 | Regenesance B V | Complement inhibition for improved nerve regeneration |
ES2545775T3 (es) | 2007-02-05 | 2015-09-15 | Apellis Pharmaceuticals, Inc. | Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio |
AU2008228247A1 (en) | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
US20110008343A1 (en) | 2007-06-08 | 2011-01-13 | Lambris John D | Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation |
WO2009014633A1 (en) | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
WO2009015087A2 (en) | 2007-07-20 | 2009-01-29 | Potentia Pharmaceuticals, Inc. | Compositions and methods for treatment of trauma |
DK2252317T3 (da) | 2008-02-15 | 2014-07-14 | Univ Tufts | Behandling af makuladegeneration |
EP2254411A4 (en) | 2008-02-19 | 2012-06-13 | Univ Pennsylvania | COMPLEMENT INHIBITORS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
US20110293524A1 (en) | 2008-02-29 | 2011-12-01 | The Brigham and Women"s Hosptial Inc. | Methods and compositions for the regulation of lectin complement pathway (lcp)-associated complement activation in hyperglycemic myocardial damage |
EP2278987A4 (en) | 2008-03-28 | 2012-08-22 | Apellis Ag | MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM |
US20090324585A1 (en) | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
AU2009283889A1 (en) | 2008-08-20 | 2010-02-25 | The Trustees Of Columbia University In The City Of New York | Complement inhibitors for treatment of injury from intracerebral hemorrhage |
DE102008049136B4 (de) | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
AU2009298684B2 (en) | 2008-09-30 | 2015-11-19 | Konstantinos Ritis | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
CN109045296A (zh) | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
WO2010057084A1 (en) | 2008-11-14 | 2010-05-20 | Novelmed Therapeutics, Inc. | Method of treating ischemia reperfusion injury |
GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
BR112012022214A2 (pt) | 2010-03-01 | 2017-07-04 | Alexion Pharma Inc | métodos e composições para tratar doença de degos |
EP3815708A1 (en) | 2010-03-05 | 2021-05-05 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
US20130324482A1 (en) | 2010-07-09 | 2013-12-05 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of rhinosinusitis and nasal polyposis |
-
2007
- 2007-10-10 HU HUE13181901A patent/HUE026042T2/en unknown
- 2007-10-10 ES ES15187453T patent/ES2831325T3/es active Active
- 2007-10-10 PT PT151874534T patent/PT3028716T/pt unknown
- 2007-10-10 EP EP13181901.3A patent/EP2698166B1/en active Active
- 2007-10-10 ES ES13181901.3T patent/ES2557056T3/es active Active
- 2007-10-10 LT LTEP15187453.4T patent/LT3028716T/lt unknown
- 2007-10-10 SI SI200731715T patent/SI2698166T1/sl unknown
- 2007-10-10 DK DK15187453.4T patent/DK3028716T3/da active
- 2007-10-10 HU HUE15187453A patent/HUE052964T2/hu unknown
- 2007-10-10 SI SI200732164T patent/SI3028716T1/sl unknown
- 2007-10-10 WO PCT/NL2007/050490 patent/WO2008044928A1/en active Application Filing
- 2007-10-10 PT PT131819013T patent/PT2698166E/pt unknown
- 2007-10-10 PL PL15187453T patent/PL3028716T3/pl unknown
- 2007-10-10 US US12/445,037 patent/US8703136B2/en active Active
- 2007-10-10 JP JP2009532314A patent/JP2010505946A/ja active Pending
- 2007-10-10 CA CA2980614A patent/CA2980614A1/en not_active Withdrawn
- 2007-10-10 AU AU2007307375A patent/AU2007307375B2/en active Active
- 2007-10-10 DK DK13181901.3T patent/DK2698166T3/en active
- 2007-10-10 EP EP15187453.4A patent/EP3028716B1/en active Active
- 2007-10-10 CA CA3154415A patent/CA3154415A1/en active Pending
- 2007-10-10 CA CA2666466A patent/CA2666466C/en active Active
- 2007-10-10 PL PL13181901T patent/PL2698166T3/pl unknown
- 2007-10-10 EP EP20196037.4A patent/EP3804755A1/en active Pending
- 2007-10-10 EP EP07834628A patent/EP2073898A1/en not_active Withdrawn
- 2007-10-10 NZ NZ576195A patent/NZ576195A/en unknown
-
2013
- 2013-06-07 JP JP2013120925A patent/JP2013189470A/ja active Pending
-
2014
- 2014-03-12 US US14/206,013 patent/US20140255395A1/en not_active Abandoned
- 2014-08-13 HK HK14108297.7A patent/HK1194688A1/zh unknown
-
2016
- 2016-12-06 HK HK16113905A patent/HK1225620A1/zh unknown
-
2017
- 2017-08-09 US US15/673,167 patent/US20180022824A1/en not_active Abandoned
-
2020
- 2020-11-13 CY CY20201101076T patent/CY1123734T1/el unknown
-
2022
- 2022-04-05 US US17/713,675 patent/US20220227884A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225620A1 (zh) | 改善的神經再生的補充抑制 | |
IL257418A (en) | Methods for treating addiction | |
EP2083857A4 (en) | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA | |
IL198851A0 (en) | Methods for treating hypercholesterolemia | |
EP2079414A4 (en) | SYSTEM FOR CHEMOHYPER THERMAL TREATMENT | |
AP2009004746A0 (en) | Process for prepaiIrng diaminophenothiazinium compounds | |
SI2545939T1 (sl) | Tetrahidrobiopterin za zdravljenje stanj povezanih s povišanimi nivoji fenilalanina | |
EP2222343A4 (en) | PROCESS FOR SUPPRESSING FASCINE | |
IL184575A0 (en) | Synergistic combinations for treating hypertension | |
EP2083777A4 (en) | RETINAL REGENERATION | |
EP2081437A4 (en) | METHODS OF TREATING OR PREVENTING INFESTATION | |
IL198856A0 (en) | Compounds useful for treating neurodegenerative disorders | |
GB0810364D0 (en) | Improved effluent treatment | |
HK1139856A1 (en) | Methods for treating acute pain | |
EG26656A (en) | Method of regeneration of rubber | |
EP2329025A4 (en) | PANCREATIC REGENERATION INDICATED BY PERIOSTIN | |
PL2043792T3 (pl) | System do obróbki ciągłej | |
HK1138187A1 (en) | Nerve regeneration agent | |
EP2192904A4 (en) | METHODS OF INHIBITING TGF- | |
IL194373A0 (en) | Methods for treating kidney disorders | |
ZA200903242B (en) | Treatment for multiple myeloma | |
ZA200901672B (en) | Compounds for treating proliferative disorders | |
EP2103304A4 (en) | COMPOSITION FOR IMPROVING BRAIN FUNCTION | |
EP1981976A4 (en) | METHOD FOR CREATING TRANSCRIPTOSOME PROFILES | |
ZA201000867B (en) | Methods for treating dependence |